Avery Therapeutics
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat diseases and injuries to human muscle. Avery’s lead product, MyCardia™, is being developed to address and treat heart failure.
What matters now
- $8.47Msold on Form D
Filed a Form D on 19 Aug 2026: $8.47M sold on Form D. A Form D is an offering filing; it names no investors, stage or valuation.
A company that just raised has fresh capital, a new board and new vendors to choose.
- 1 investornamed
1 investor on record.
The investors already on the cap table shape who leads the next round.
- 2 directorsboard
2 directors on record from Form D filings and board-seat attributions.
The board is who decides on the next round and on a sale.
Facts
- Year of incorporation
- unknown
- Revenue range (Form D)
- Decline to Disclosesec.gov
- Rounds on record
- 1
- Disclosed raised
- unknownsum of rounds with a disclosed amount only
- Named investors
- 1
Financing history
- Aug 19, 2026Form D equity offering · $8.5M (form d sold) · 23 investorsFact Form D · “Avery Therapeutics, Inc. filed Form D: $8,468,859 sold of $15,400,000, Biotechnology”
Investors on record
- Service Provider Capital portfolio listing Fact serviceprovidercapital.com
Ownership and outcomes
How these are wordedA company a buyout or growth firm lists on its own site is “listed in the portfolio of”, never “acquired by”. A date prints only when a deal record gives one; otherwise the row says when DFX first saw it.Listed on 1 firm portfolio page; none states an outcome (acquired, public, exited or active). DFX does not assume the company is active.
Evidence: 1 listingeach firm's own card, as read
- Status not stated on Service Provider Capital · the firm's card prints no outcome · read Oct 1, 2026 serviceprovidercapital.com“Avery Therapeutics”
Credit relationships
How a loan is matchedA BDC reports its loans by borrower name. A position shows here only when the match passed a precision gate (a hand-labelled sample was 29 of 30 correct); the tier and confidence are printed on each row. Amounts are the lender’s reported position, never a round.People
- Jordan Lancaster Executive Officer/Director sec.gov
- Steven Goldman Executive Officer sec.gov
- Lawrence Mehren Director Fact
- Emile Nuwaysir Director Fact
Timeline
- Sep 21, 2026Avery Therapeutics, Inc. filed Form D: $8,468,859 sold of $15,400,000, BiotechnologyForm D filed Fact Form D
Evidence
Every observation on this company
- Description: Sep 21, 2026 Fact Company website
- Entity type: Corporation Sep 21, 2026 Fact Form D
- Form D industry group: Biotechnology Sep 21, 2026 Fact Form D
- Amendment: false Sep 21, 2026 Fact Form D
- Revenue range (Form D): Decline to Disclose Sep 21, 2026 Fact Form D
- Incorporated: overFiveYears Sep 21, 2026 Fact Form D
- Jurisdiction: Delaware Sep 21, 2026 Fact Form D
- Amount sold (Form D): $8.5M Sep 21, 2026 Fact Form D
- Offering amount (Form D): $15.4M Sep 21, 2026 Fact Form D
- Exemptions: 06b Sep 21, 2026 Fact Form D
- First sale: 2026-08-19 Sep 21, 2026 Fact Form D
- Investors (Form D): 23 Sep 21, 2026 Fact Form D
- Minimum investment (Form D): 0 Sep 21, 2026 Fact Form D
- Securities offered: equity Sep 21, 2026 Fact Form D
- Office address: Sep 21, 2026 Fact Form D
- Listed on portfolio page: Service Provider Capital Oct 1, 2026 Fact Firm website
- Listed on portfolio page: Service Provider Capital Sep 16, 2026 Fact Firm website
- Listed on portfolio page: Service Provider Capital Sep 15, 2026 Fact Firm website
- Website status: ok Sep 21, 2026 Fact Company website
- Site title: Sep 21, 2026 Fact Company website
Record history
- Form D filed2026-09-21source on record
The ledger records every merge, rename and reclassification this record went through and the dated filings observed on it, so the identity on this page can be traced to the records it was built from. The ledger's own sentences name other records, so they show with the names.